ReviewDrugs2003
Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.
Review in Drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 379 citations in OpenAlex.
- Comparison of Ceftolozane-Tazobactam Versus Meropenem Regimens in Treating Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-ProducingJournal of clinical medicine · 2026Article
- Clinical Predictors and Pathogen Resistance Dynamics in Hospitalized Patients with Urinary Tract Infections: A 2025 Institutional Study.Microorganisms · 2026Article
- Dynamic 16S rRNA Sequencing of the Abdominal Wall Surgical Site Highlights Potential Pathways of Incisional Surgical Site Infection in Colorectal Surgery.ANZ journal of surgery · 2026Article
- Phylodynamic estimation of the within-host evolutionary rate of extended-spectrum beta-lactamase-producing Enterobacterales.Microbial genomics · 2025Article
- Biofilm Formation and Antibiotic Resistance Genes of Escherichia coli From Poultry Farms and Clinical Samples.Veterinary medicine and science · 2025Article
- In Vitro Activity of Cefaclor/Beta-Lactamases Inhibitors (Clavulanic Acid and Sulbactam) Combination Against Extended-Spectrum Beta-Lactamase Producing UropathogenicAntibiotics (Basel, Switzerland) · 2025Article
- Genetic diversity and antibiogram of ESBL-producing Escherichia coli isolated from apparently healthy birds sold at two selected live bird markets in Nigeria.Molecular biology reports · 2025Article
- Emerging Trends of Beta-Lactamases in Western Nepal: A Growing Public Health Concern.International journal of microbiology · 2025Article
- Insight into the Prevalence of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Vegetables: A Systematic Review and Meta-Analysis.Foods (Basel, Switzerland) · 2024Review
- Multicenter study on clinical outcomes and poor prognostic factors in patients with Klebsiella pneumoniae bacteremia receiving cefoperazone/sulbactam treatment.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Exploring Extended-Spectrum Beta-Lactamase (ESBL)-ProducingPathogens (Basel, Switzerland) · 2024Review
- Article
- Carbapenem-ResistantMedicina (Kaunas, Lithuania) · 2024Review
- Distribution ofMedicine in microecology · 2023Article
- Extended Spectrum β-Lactamase-Producing Enterobacterales of Shrimp and Salmon Available for Purchase by Consumers in Canada-A Risk Profile Using the Codex Framework.Antibiotics (Basel, Switzerland) · 2023Review
- Epidemiological study of antimicrobial-resistant bacteria in healthy free-ranging bantengs (Veterinary world · 2023Article
- Genomic Characterization of FecalPathogens (Basel, Switzerland) · 2023Article
- Molecular responses during bacterial filamentation reveal inhibition methods of drug-resistant bacteria.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Cooperative antibiotic resistance facilitates horizontal gene transfer.The ISME journal · 2023Article
- Multidrug-Resistant ESBL-ProducingAntibiotics (Basel, Switzerland) · 2023Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended spectrum beta-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10-40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs. ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading. Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC beta-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by beta-lactamase inhibitors such as clavulanic acid, the activity of beta-lactam/beta-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.